Protagenic Therapeutics updates PT00114 milestones: Phase I multi-dose Q4 2024, Phase IIa Q3 2025

Protagenic Therapeutics, Inc.new

Multiple dose portion of Phase I study for PT00114 expected to commence Q4 2024.
Results from multiple dose portion of Phase I study for PT00114 expected Q2 2025.
Initiation of Phase IIa study for PT00114 expected Q3 2025.
Company will provide further updates to clinical development schedule as it becomes clearer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.